Rapamycin inhibits the in vitro release of soluble CD23 by SAC/IL-2/IL-4-activated human peripheral blood B lymphocytes.
Degiannis
D
D
Division of Clinical Immunology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, USA.
Hornung
N
N
D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism* / Q000382:microbiology; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology*; D008213:Lymphocyte Activation; D011090:Polyenes / Q000494:pharmacology*; D017455:Receptors, IgE / Q000378:metabolism*; D020123:Sirolimus; D012995:Solubility; D013211:Staphylococcus aureus / Q000737:chemistry / Q000502:physiology*
D007376:Interleukin-2; D011090:Polyenes; D017455:Receptors, IgE; D015847:Interleukin-4; D020123:Sirolimus